Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test
Atomo Diagnostics (AT1) receives approval to supply its HIV Self-Test to a…
Atomo Diagnostics Limited (ASX:AT1)
19.0¢
-0.005 (-2.56%)
MCAP $110.8M
Last trade
12.32pm 06/12/2021
20mins delayed
Latest Announcements
26/11/2021AT1Atomo Diagnostics Limited
1,637
MCap
25/11/2021AT1Atomo Diagnostics Limited
1,086
MCap
10/11/2021AT1Atomo Diagnostics Limited
2,018
MCap
08/11/2021AT1Atomo Diagnostics Limited
797
MCap
08/11/2021AT1Atomo Diagnostics Limited
28/10/2021AT1Atomo Diagnostics Limited
298
MCap
28/10/2021AT1Atomo Diagnostics Limited
2,187
MCap
28/10/2021AT1Atomo Diagnostics Limited
248
MCap
Company Overview
Atomo Diagnostics Ltd is an Australia-based medical device company. The Company is engaged in the development and sale of medical devices. Its AtomoRapid is offering rapid diagnostic test (RDT) platform, which provides devices to the global diagnostic market. Its RDT device platforms include Galileo, Pascal, Losev, Newton, Franklin and Elion. It also offers blood-based rapid diagnostic test (RDT) for screening for human immunodeficiency virus (HIV). Its RDT platform includes various features, such as integrated lancelet, blood collection, buffer delivery and digital display. It is also engaged in sales of Atomo branded COVID-19 rapid antibody and antigen tests in Australia.
